Dx&Vx

IR Letter

(Mar. 2025)

Dx&Vx Business Roadmap



Dx

Medical Diagnostics

Dx&Vx's genomic diagnostics and in vitro diagnostics contribute to reducing healthcare costs and improving treatment outcomes. Genomic diagnostic technologies enable more precise and personalized treatments, combined with new drug developments, driving innovation in the medical field. Our companion diagnostic services enhance the efficacy of both our own and third-party drug developments, minimizing side effects and facilitating the development of personalized treatment options for patients.

- Genomic Diagnostics
- In Vitro Diagnostics and CDMO
- Genomics CRO
- Companion Diagnostic Services (CliDex)

HFF

Consumer Healthcare

Using our diagnostic technologies, we provide integrated consumer healthcare solutions based on the microbiome for disease prevention, treatment, and management. Our services include health functional foods for prevention, general pharmaceuticals and prescription drugs for treatment, and products for lifestyle and hygiene management. We target the global market and continue to achieve high sales growth.

- Microbiome-based Therapeutic Adjuncts
- Nutrition Products
- Domestic and International CSO
- Functional Skincare/Personal Hygiene Products

Vx

Drug Development

We are actively advancing the development of various novel therapeutics, including the long-term storage mRNA vaccine platform, immuno-oncology therapies, oral obesity treatments, and vaccines and therapeutics for infectious diseases, while expanding collaborations with global pharmaceutical companies. In 2025, we expect major platform technologies to yield tangible results, driving the commercialization of new drug development, revenue growth, and the establishment of a sustainable clinical reinvestment cycle to ensure long-term growth.

- Vaccine
- mRNA Vaccine and Diagnostic Platform
- Obesity and Metabolic Diseases
- Anticancer Drug
- Ophthalmic Therapeutics
- Antiviral Drug

DH

Digital Healthcare

Dx&Vx is on the verge of launching K-hub, a bio-pharmaceutical portal, combined with our genomic analysis platform and telemedicine services. We aim to shift from a treatment-centric to a prevention and management-focused approach in healthcare services, ultimately aiming to develop a Clinical Decision Support System (CDSS) to assist medical professionals in their decision-making.

- K-hub
- Telemedicine Services
- AI-based Drug Development Platform
- Smart Diagnostic Devices

Performance Summary for February 2025

- Negotiations and Due Diligence for the Licensing of the Long-Term Storage mRNA Vaccine Platform and Drug Pipeline
- Development Status of Next-Generation Universal Coronavirus Vaccine and Therapeutics for Future Pandemic Preparedness
- Signing of a Precision Medicine Service Supply Agreement with Panacura, a Company Developing Herbal Medicine-Based Therapeutics
- Securing Financial Stability and Ensuring Sustainable Growth

Drug Development

Negotiations and Due Diligence for the Licensing of the Long-Term Storage mRNA Vaccine Platform and Drug Pipeline

Our company is actively engaged in negotiations with domestic and international companies for the licensing of our long-term storage mRNA vaccine platform and drug pipeline and has initiated the due diligence process to facilitate these agreements.

First, our mRNA vaccine platform technology, for which we have secured exclusive commercialization rights from POSTECH (Pohang University of Science and Technology), is an innovative breakthrough designed to overcome the storage and distribution limitations of conventional mRNA vaccines. This technology significantly enhances the stability of mRNA, enabling storage at ambient temperatures for over 10 years, which is expected to establish a new paradigm in the global vaccine market. Currently, we are in discussions with multiple overseas companies through our global network, including the J.P. Morgan Healthcare Conference, and are in the final review stage for Material Transfer Agreements (MTA) with domestic pharmaceutical and biotechnology firms. Some negotiations have progressed to the online due diligence phase, and in the case of partners advancing swiftly, Term Sheet discussions will commence immediately upon completion of the due diligence process.

Additionally, we are conducting due diligence for the technology transfer of DX-DRG-C01, our investigational obesity treatment, with both domestic and global pharmaceutical companies. This treatment is based on a novel chemical structure and has demonstrated excellent pharmacokinetics (PK) and strong efficacy in preclinical studies. Our goal is to complete formal toxicology studies within the year and advance into the clinical development phase.

Development Status of Next-Generation Universal Coronavirus Vaccine and Therapeutics for Future Pandemic Preparedness

Our company is actively advancing the development of a universal coronavirus preventive vaccine and antiviral therapeutics to prepare for future pandemics. We are currently preparing for a global Phase 2 clinical trial for our universal coronavirus vaccine, while simultaneously progressing our antiviral therapeutic candidate through preclinical studies and into Phase 1 clinical trials, with the goal of rapidly responding to emerging coronavirus variants.

In December of last year, we acquired the technology for a universal coronavirus vaccine from Stanford University. This vaccine utilizes a ferritin platform-based virus-like particle (VLP) technology, which induces a strong immune response and is theoretically capable of protecting against all coronavirus variants. Prior to our technology acquisition, Phase 1 clinical trials were successfully completed in the United States and South Africa, and we have since completed the protocol design for a global Phase 2 clinical trial.

Additionally, we have accelerated our antiviral therapeutic development. In December of last year, we signed a joint research agreement with LUKA AICell to develop a universal antiviral peptide-based therapeutic that physically disrupts viral envelopes. LUKA's platform technology targets the structural curvature of viral envelopes below a specific size, effectively neutralizing them through a novel mechanism of action. Based on this technology, we are currently preparing for an Investigational New Drug (IND) application for a Phase 1 clinical trial.

Drug Development

Signing of a Precision Medicine Service Supply Agreement with Panacura, a Company Developing Herbal Medicine-Based Therapeutics

Our company has signed a precision personalized medicine service supply agreement with Panacura, a company specializing in the development of herbal medicine-based therapeutics. Under this agreement, we will provide precision medicine analysis services, while Panacura will distribute these services through its network of oriental medicine hospitals and clinics. Beyond the co-development of in vitro diagnostic medical devices, both companies plan to expand their collaboration to include precision medicine analysis services applicable in oriental medicine clinics, thereby accelerating commercialization efforts.

Leveraging our nation's largest clinical genomic database, we expect to drive the digital transformation of oriental medicine and innovation in precision healthcare. Given the market potential of precision medicine services in oriental medicine, we anticipate generating annual revenue exceeding KRW 10 billion in this sector.

Management

Securing Financial Stability and Ensuring Sustainable Growth

Our company is actively addressing market concerns following our February 13 disclosure regarding the risk of being designated as a managed stock and is strengthening strategies for sustainable growth. While short-term financial burdens have increased due to investments in R&D and pipeline expansion, we have implemented concrete countermeasures to resolve these challenges and are focused on maximizing corporate value over the mid-to-long term.

▶ **Measures to Secure Financial Stability**

On February 28, 2025, we secured a KRW 20 billion loan, which will be utilized to accelerate new drug development and support operational expenses. This financing was facilitated under the leadership of our largest shareholder, Chairman Jong-Yoon Lim, as part of his commitment to strengthening responsible management. This capital injection is expected to serve as a foundation for the normalization of corporate value and sustainable growth. With ongoing global licensing-out negotiations and the commercialization of drug development milestones, this funding is anticipated to be a critical turning point in sustaining R&D and business operations. Starting this year, we expect to see substantial R&D achievements, further reinforcing our financial soundness.

▶ **Growth Momentum Through Drug Development and Licensing-Out**

DXVX possesses a diverse portfolio of innovative drug pipelines, enhancing its competitiveness in the global pharmaceutical market. Our key ongoing projects include:

- Universal coronavirus vaccine and therapeutics: Preparing for global Phase 2 clinical trials and advancing preclinical research.
- Oral obesity treatment: Engaged in licensing-out negotiations with global pharmaceutical companies.
- Long-term storage mRNA vaccine platform: Undergoing due diligence with global partners.
- ROP cancer vaccine, antibody-based oncology therapies, microbiome-based vaccines, and more: Advancing clinical research and patent filings for multiple drug candidates.

We are currently conducting licensing-out negotiations with multiple global pharmaceutical and biotechnology companies. Once due diligence is completed, we anticipate engaging in Term Sheet discussions with potential partners. These licensing deals are expected to generate meaningful revenue from our drug pipeline, helping to establish a sustainable growth model based on R&D achievements.

▶ **Growth Prospects in Pharmaceuticals and Healthcare Business**

Beyond new drug development, our company is also expanding its presence in the pharmaceutical and healthcare sectors. We are strengthening our pharmaceutical distribution network through our Chinese subsidiary, particularly by expanding our antibiotic and essential drug portfolio. Additionally, we are reinforcing our brand presence in the health supplement and therapeutic support markets. With increasing exports to China and Vietnam, and plans for further expansion into Japan and the United States, we are pursuing both market diversification and profitability improvements.

Through proactive business strategies and financial stability measures, our company is committed to restoring market confidence and maximizing shareholder value.